Abstract:
:The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LTMAs and suicidal behaviour. We conducted a literature search of MEDLINE, EMBASE and International Pharmaceutical Abstracts from 1995 to 2010 (inclusive) to identify pertinent studies and reports. We also examined data obtained from the FDA adverse event reporting system. To date, there are no well conducted, comparative, observational studies of this association, and the safety alerts are based primarily on case reports. While the FDA safety alerts apply to all three LTMAs, montelukast (known by its trade name Singulair®) is by far the most widely used of these drugs and most of the reports to date regarding suicide pertain to montelukast. From 1998 to 2009 there were 838 suicide-related adverse events associated with leukotrienes reported to the FDA, of which all but five involved montelukast. Nearly all cases were reported in 2008 and 2009 (96.1%) after the FDA warnings. LTMAs are approved for use in asthma and allergic rhinitis, and are effective drugs. Both of these diseases are also associated with suicide, making confirmation of the association more difficult. Given the lack of good evidence, we recommend that a large observational cohort or case-control study be conducted to quantify the association between LTMAs and suicide. Until then, when prescribing LTMAs, clinicians should consider the potential for suicide and monitor patients who may be at elevated risk carefully for suicidal ideation or psychiatric symptoms associated with suicidal behaviour.
journal_name
Drug Safjournal_title
Drug safetyauthors
Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RDdoi
10.2165/11587260-000000000-00000subject
Has Abstractpub_date
2011-07-01 00:00:00pages
533-44issue
7eissn
0114-5916issn
1179-1942pii
1journal_volume
34pub_type
杂志文章,评审相关文献
DRUG SAFETY文献大全abstract::Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common disorders: irritable bowel syndrome and inflammatory bowel disease. Since a wide variety of probiotic preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity exist...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-015-0349-x
更新日期:2016-04-01 00:00:00
abstract::The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary prophylaxis of patients with venous thromboembolism. Even though NOACs have a better safety profile than vitamin K antagonists (VKAs), there wi...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-015-0357-x
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200023040-00006
更新日期:2000-10-01 00:00:00
abstract:BACKGROUND:Fatal venous thromboembolism (VTE) is a rare complication of combined oral contraceptive (COC) treatment. This study aims to determine incidences of fatal VTE in relation to the type of COC and the percentage of cases reported to the Swedish Adverse Drug Reactions Advisory Committee (SADRAC). A further aim i...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200528100-00007
更新日期:2005-01-01 00:00:00
abstract:INTRODUCTION AND OBJECTIVE:Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, wh...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-015-0383-8
更新日期:2016-02-01 00:00:00
abstract::Methylphenidate is the most widely use psychotropic medication in children in the US. It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects. However, the abuse of methylphenidate for the purpose of experiencing a 'high...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199717030-00001
更新日期:1997-09-01 00:00:00
abstract:BACKGROUND AND PURPOSE:Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed in the elderly due to a more favorable risk profile than other antidepressants (ADs). However, SSRIs are associated with an increased risk of gastrointestinal bleeding, while evidence on the risk of hemorrhagic stroke (HS) ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-019-00837-y
更新日期:2019-09-01 00:00:00
abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-018-0760-1
更新日期:2019-05-01 00:00:00
abstract:INTRODUCTION:Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. OBJECTIVE:Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the cardiovascular effects of once-daily valbenazine in patients with a psyc...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-017-0623-1
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...
journal_title:Drug safety
pub_type: 杂志文章,meta分析,评审
doi:10.2165/11598050-000000000-00000
更新日期:2012-03-01 00:00:00
abstract:BACKGROUND:Academic medical centres face the need to care for patients with complex medical conditions, educate physicians-in-training and conduct research, all with increasingly constrained budgets. The adoption of new therapeutic technology presents challenges and opportunities in each of these areas. Severe sepsis r...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200427150-00008
更新日期:2004-01-01 00:00:00
abstract::Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-017-0625-z
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited. OBJECTIVE:To retrospectively assess the safety profile of interferon-beta-1a therapy with respect to liver function durin...
journal_title:Drug safety
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00002018-200326110-00006
更新日期:2003-01-01 00:00:00
abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-016-0419-8
更新日期:2016-08-01 00:00:00
abstract::The risks and adverse effects of the low dose, new generation progestogen combined oral contraceptives (COCs) are much lower than original studies involving pills containing 50 micrograms estrogen. The main effects are those on the cardiovascular system, lipid and glucose metabolism and cancer. Any effect of the COC o...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199512020-00002
更新日期:1995-02-01 00:00:00
abstract:BACKGROUND:Depressive disorders and use of antidepressants are associated with adverse effects on sexual function. In pharmacoepidemiological studies, sexual disorders are reported by more than 50 % of patients taking serotonin reuptake inhibitors (SRIs). OBJECTIVE:The aim of this study was to determine the reporting ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-013-0069-z
更新日期:2013-07-01 00:00:00
abstract::It has been more than 25 years since an adverse drug reaction (ADR) monitoring agency was first established in China. In the past few years, the National ADR Monitoring System (NADRMS) has developed rapidly in the country. However, this system has not been reviewed in detail in the literature. Our aim was to demonstra...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-016-0446-5
更新日期:2016-11-01 00:00:00
abstract::Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease. The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons, and thus accelerate the deterioration of the patient's condition. Evi...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199921050-00001
更新日期:1999-11-01 00:00:00
abstract::Pharmacotherapy in pregnant women is often necessary to treat chronic or relapsing depression or anxiety disorders. Studies that have evaluated the safety of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy have not shown an enhanced risk of major congenital malformations and these results may have c...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200528070-00002
更新日期:2005-07-01 00:00:00
abstract:BACKGROUND:Problematic prescription drug use is reflected by or associated with drug-seeking aberrant behaviours. Research gaps include lack of post-marketing evidence and instruments. As part of the pharmacovigilance requirements, a risk management plan was developed for fentanyl buccal tablets (FEBT) by the manufactu...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-014-0193-4
更新日期:2014-08-01 00:00:00
abstract::With the introduction of several new anticonvulsant drugs into clinical practice in recent years, renewed attention has been paid to treatment-emergent effects, especially behavioural syndromes. In this review, the more severe psychiatric syndromes that may be associated with anticonvulsants are discussed, especially ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199615030-00001
更新日期:1996-09-01 00:00:00
abstract:: ...
journal_title:Drug safety
pub_type: 评论,信件
doi:10.1007/s40264-018-0716-5
更新日期:2018-12-01 00:00:00
abstract::Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based regimens are effective treatment options for patients with HIV at various stages of disease. In vitro studies of HIV-infected lymphocytes have shown that hydroxyurea: (i) inhibits viral DNA synthesis; (ii) synergistically in...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200326090-00002
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:It has been shown that the abrupt cessation of treatment with beta-adrenoceptor antagonists (beta-blockers) increases the risk of myocardial infarction in patients with hypertension. As beta-blockers differ in their pharmacokinetic and pharmacodynamic properties, this risk of discontinuation might also diffe...
journal_title:Drug safety
pub_type: 临床试验,杂志文章
doi:10.2165/00002018-200730060-00008
更新日期:2007-01-01 00:00:00
abstract:INTRODUCTION:Electronic healthcare databases (EHDs) are used increasingly for post-marketing drug safety surveillance and pharmacoepidemiology in Europe and North America. However, few studies have examined the potential of these data sources in China. METHODS:Three major types of EHDs in China (i.e., a regional commu...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-017-0589-z
更新日期:2018-01-01 00:00:00
abstract::The most frequently reported symptoms in heart failure are fatigue and dyspnoea, which limit exercise tolerance. However, several surveys reveal other changes in physical and psychological well-being which affect the patient's perception of 'quality of life'. The introduction of new treatments for heart failure has st...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199106040-00002
更新日期:1991-07-01 00:00:00
abstract:BACKGROUND:The use of data mining has increased among regulators and pharmaceutical companies. The incremental value of data mining as an adjunct to traditional pharmacovigilance methods has yet to be demonstrated. Specifically, the utility in identifying new safety signals and the resources required to do so have not ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11319000-000000000-00000
更新日期:2010-02-01 00:00:00
abstract::Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200225020-00002
更新日期:2002-01-01 00:00:00
abstract::Rhythm control in atrial fibrillation (AF) can be achieved using pharmacological therapy. Amiodarone is the most efficacious anti-arrhythmic agent; however, its use is limited due to an unfavourable safety profile, including pro-arrhythmia, thyroid, liver, skin and pulmonary complications. Dronedarone, which is struct...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-012-0012-8
更新日期:2013-02-01 00:00:00
abstract:INTRODUCTION:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were associated with a risk of neurocognitive adverse drug reactions (ADRs). OBJECTIVE:We aimed to investigate the occurrence of neuropsychiatric ADRs related to PCSK9Is. METHODS:We analyzed Individual Case Safety Reports (ICSRs) sent thr...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-020-01021-3
更新日期:2020-12-22 00:00:00